title: Expected developments in hepatology.
abstract: It is very difficult to predict new developments in hepatology so we have decided to analyse the most important issues related to three clinical conditions in hepatology. The first is chronic hepatitis. Here, we discuss the relevance of occult forms of hepatitis B virus infection in the development of cryptogenic liver disease and hepatocellular carcinoma. In addition, the role of genotyping in hepatitis B is analysed, indicating that patients with genotype A have a better prognosis than those with genotype D. The treatment of hepatitis B virus infection is also reviewed, and it has been suggested that research should be directed towards the development of new anti-viral agents to suppress virus replication. The natural history of hepatitis C virus infection is considered, emphasizing the need to know the progression of fibrosis in these patients. The chapter also suggests that treatment of hepatitis C virus infection with pegilated interferon and ribavirin is currently relatively effective. New therapeutic strategies will be required in the future, the most important challenge being the development of a hepatitis C virus vaccine. The second section is on chronic cholestasis. The role of anti-mitochondrial antibodies in primary biliary cirrhosis is considered. The possible infectious agents implicated as potential triggers of primary biliary cirrhosis are also discussed, suggesting that several infections may play a role in the pathogenesis of this condition. Other aetiopathogenic factors, for example organic compounds, drugs and chemicals, are indicated. It is possible that, in the near future, the precise sequence and molecular basis by which infectious agents or xenobiotics may initiate the cascade of the autoimmune response will be defined. One of the most important challenges in primary sclerosing cholangitis concerns the mechanisms that may induce the development of this disease. Up until now, genetic factors have been suggested, recent data reporting a clear-cut association between primary sclerosing cholangitis and the tumour necrosis factor-alpha(2) allele. The third part of this chapter includes recent progress achieved in hepatocellular carcinoma, discussing developments in the knowledge of hepatocellular carcinogenesis. Hepatocellular carcinomas appear so far to be genetically heterogeneous neoplasms, and this heterogeneity may correlate with the variety of aetiological factors involved. The risk factors and primary, secondary and tertiary prevention of the condition are also analysed. Finally, the development of new therapeutic strategies for hepatocellular carcinoma is evaluated by evidence-based studies.
authors.affiliation: Liver Unit, Hospital Clínic, Institut d'Investigaciones Biomédiques August Pi i Sunyer, University of Barcelona, Spain.
authors.forename: Xavier
authors.initials: X
authors.lastname: Forns
authors.forename: José M
authors.initials: JM
authors.lastname: Sánchez Tapias
authors.forename: Albert
authors.initials: A
authors.lastname: Parés
authors.forename: Josep M
authors.initials: JM
authors.lastname: Llovet
authors.forename: Jordi
authors.initials: J
authors.lastname: Bruix
authors.forename: Juan
authors.initials: J
authors.lastname: Rodés
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular; D015209:Cholangitis, Sclerosing; D002779:Cholestasis; D005762:Gastroenterology / Q000639:trends*; D006521:Hepatitis, Chronic; D006801:Humans; D008105:Liver Cirrhosis, Biliary; D008113:Liver Neoplasms
chemical_list: D000998:Antiviral Agents